These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 2169340)
1. An enzyme-linked immunosorbent assay for cancer procoagulant and its potential as a new tumor marker. Gordon SG; Cross BA Cancer Res; 1990 Oct; 50(19):6229-34. PubMed ID: 2169340 [TBL] [Abstract][Full Text] [Related]
2. Activity of cancer procoagulant (CP) in serum of patients with cancer of lung, breast, oesophagus and colorectum. Rucińska M; Furman M; Skrzydlewski Z; Zaremba E Acta Biochim Pol; 1997; 44(1):109-12. PubMed ID: 9241361 [TBL] [Abstract][Full Text] [Related]
3. New immunocapture enzyme (ICE) assay for quantification of cancer procoagulant activity: studies of inhibitors. Mielicki WP; Tagawa M; Gordon SG Thromb Haemost; 1994 Apr; 71(4):456-60. PubMed ID: 8052963 [TBL] [Abstract][Full Text] [Related]
4. The detection of quantitative serum p53 protein in lung cancer. Sen E; Gönüllü U; Akar N Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881 [TBL] [Abstract][Full Text] [Related]
5. Nonspecific cross-reacting antigen 50/90 is elevated in patients with breast, lung, and colon cancer. Allard WJ; Neaman IE; Elting JJ; Barnett TR; Yoshimura H; Fritsche HA; Yeung KK Cancer Res; 1994 Mar; 54(5):1227-34. PubMed ID: 8118811 [TBL] [Abstract][Full Text] [Related]
6. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients. Schneider J; Peltri G; Bitterlich N; Neu K; Velcovsky HG; Morr H; Katz N; Eigenbrodt E Anticancer Res; 2003; 23(2A):899-906. PubMed ID: 12820320 [TBL] [Abstract][Full Text] [Related]
7. Serum matrix metalloproteinases -2, -9 and tissue inhibitors of metalloproteinases -1, -2 in lung cancer--TIMP-1 as a prognostic marker. Ylisirniö S; Höyhtyä M; Turpeenniemi-Hujanen T Anticancer Res; 2000; 20(2B):1311-6. PubMed ID: 10810441 [TBL] [Abstract][Full Text] [Related]
8. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection. D'Amico TA; Brooks KR; Joshi MB; Conlon D; Herndon J; Petersen RP; Harpole DH Ann Thorac Surg; 2006 Jun; 81(6):1982-7; discussion 1987. PubMed ID: 16731117 [TBL] [Abstract][Full Text] [Related]
9. Detection of blood-borne cells in colorectal cancer patients by nested reverse transcription-polymerase chain reaction for carcinoembryonic antigen messenger RNA: longitudinal analyses and demonstration of its potential importance as an adjunct to multiple serum markers. Guadagni F; Kantor J; Aloe S; Carone MD; Spila A; D'Alessandro R; Abbolito MR; Cosimelli M; Graziano F; Carboni F; Carlini S; Perri P; Sciarretta F; Greiner JW; Kashmiri SV; Steinberg SM; Roselli M; Schlom J Cancer Res; 2001 Mar; 61(6):2523-32. PubMed ID: 11289125 [TBL] [Abstract][Full Text] [Related]
10. [Cancer procoagulant activity in cases of esophageal, stomach and colorectal cancer considering progression degree and histological type of cancer]. Kozuszko B; Skrzydlewski Z; Sulkowska M; Snarska J; Kozłowski M; Skrzydlewska E; Zalewski B Pol Merkur Lekarski; 2001 Sep; 11(63):218-20. PubMed ID: 11761814 [TBL] [Abstract][Full Text] [Related]
11. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases. Schneider J; Morr H; Velcovsky HG; Weisse G; Eigenbrodt E Cancer Detect Prev; 2000; 24(6):531-5. PubMed ID: 11198266 [TBL] [Abstract][Full Text] [Related]
12. [Clinical usefulness of a new tumor marker CYFRA21-1 in patients with lung cancer]. Li R; Li R; Wang Y Zhonghua Jie He He Hu Xi Za Zhi; 1998 Jan; 21(1):26-9. PubMed ID: 11263296 [TBL] [Abstract][Full Text] [Related]
13. [Diagnostic significance of cancer procoagulant activity in colorectal cancer]. Kozuszko B; Skrzydlewski Z; Famulski W Pol Merkur Lekarski; 2000 Mar; 8(45):127-8. PubMed ID: 10870414 [TBL] [Abstract][Full Text] [Related]
14. Application of cancer procoagulant as an early detection tumor marker. Kozwich DL; Kramer LC; Mielicki WP; Fotopoulos SS; Gordon SG Cancer; 1994 Aug; 74(4):1367-76. PubMed ID: 8055461 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of the relationship between serum carcinoembryonic antigen level and treatment outcome in surgically resected clinical-stage I patients with non-small-cell lung cancer. Hotta K; Segawa Y; Takigawa N; Kishino D; Saeki H; Nakata M; Mandai K; Eguchi K Anticancer Res; 2000; 20(3B):2177-80. PubMed ID: 10928173 [TBL] [Abstract][Full Text] [Related]
16. Value of tumour and inflammatory markers in lung cancer. Oremek GM; Sauer-Eppel H; Bruzdziak TH Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794 [TBL] [Abstract][Full Text] [Related]
17. Characterization of two human small cell lung carcinoma-reactive monoclonal antibodies generated by a novel immunization approach. Tong AW; Lee J; Stone MJ Cancer Res; 1984 Nov; 44(11):4987-92. PubMed ID: 6207911 [TBL] [Abstract][Full Text] [Related]
18. Cancer procoagulant--CP. Rucińska M; Gacko M; Skrzydlewski Z Rocz Akad Med Bialymst; 1997; 42 Suppl 1():110-7. PubMed ID: 9337529 [TBL] [Abstract][Full Text] [Related]
19. New serum markers for small-cell lung cancer. II. The neural cell adhesion molecule, NCAM. Vangsted A; Drivsholm L; Andersen E; Bock E Cancer Detect Prev; 1994; 18(4):291-8. PubMed ID: 7982239 [TBL] [Abstract][Full Text] [Related]
20. [The diagnostic values of CA242 combining other tumor markers for lung cancer]. Zhang S; Ma Y; Yang X Zhonghua Jie He He Hu Xi Za Zhi; 1999 May; 22(5):271-3. PubMed ID: 11775851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]